Examorelin

Summary

Examorelin (also known as EP‑001, EP‑23905, hexarelin) is an investigational synthetic peptide that acts as a growth‑hormone‑releasing hormone (GHRH) analogue. It is being explored for its ability to stimulate endogenous growth‑hormone secretion via the growth‑hormone‑secretagogue receptor and has also been highlighted in computational screens as a potential binder of the SARS‑CoV‑2 RNA‑dependent RNA polymerase.

Mechanism of Action

Examorelin mimics the endogenous peptide ghrelin and binds to the growth‑hormone‑secretagogue type 1a receptor (GHS‑R1a) on pituitary somatotrophs. Activation of this G‑protein‑coupled receptor triggers intracellular signaling that culminates in the release of stored growth hormone into circulation. In silico docking studies suggest the peptide can also occupy the active site of the SARS‑CoV‑2 RNA‑dependent RNA polymerase, potentially interfering with viral RNA synthesis, although this antiviral mechanism is theoretical.

What the Research Shows

Three peer‑reviewed sources provide the current evidence base. A 2020 drug‑repurposing study used molecular docking to screen FDA‑approved compounds against SARS‑CoV‑2 RdRp and reported that examorelin bound strongly within the polymerase’s active pocket, suggesting a possible antiviral lead. A 2025 forensic‑toxicology investigation examined human hepatocyte metabolism of alexamorelin (a related GHS peptide) and found rapid N‑acetylation and carboxypeptidase‑mediated C‑terminal cleavage, producing examorelin as a primary metabolite; the parent compound’s signal declined ~150‑fold after 3 hours, indicating extensive hepatic processing. A 2002 clinical‑trial compendium listed examorelin among investigational agents but provided no outcome data. No clinical trials, efficacy endpoints, or safety assessments are reported in these abstracts.

Reported Benefits

The available data confirm that examorelin can activate the GHS‑R1a pathway, which is known to increase endogenous growth‑hormone release, offering a mechanistic basis for potential applications in growth‑deficiency or muscle‑mass contexts. Computational models also suggest a possible antiviral interaction with SARS‑CoV‑2 RdRp, providing a hypothesis for future drug‑development efforts.

Limitations of the Evidence

Evidence is confined to in silico docking and in vitro metabolism; no human pharmacodynamic, efficacy, or safety studies have been published. The antiviral claim lacks experimental validation, and the metabolic study indicates rapid clearance, which may limit systemic exposure. Regulatory approval has not been granted, and the compound remains investigational.

Safety Considerations

The cited literature does not report adverse‑event data for examorelin. The rapid hepatic metabolism observed for related alexamorelin suggests the peptide is quickly transformed in the liver, but the clinical significance of this metabolism is unknown. Without human safety studies, potential side effects, including those related to excessive growth‑hormone secretion (e.g., edema, insulin resistance), remain speculative.

How It Is Administered

Examorelin has been formulated for intranasal, intravenous, and subcutaneous delivery in experimental settings. The specific dosage forms and concentrations are not detailed in the available abstracts, and the compound is not approved for any therapeutic indication.

Routes of Administration

Goals & Uses

• Increase GH secretionEndocrineModerate
• Treat adult GH deficiencyTherapeuticLow
• Cachexia / muscle wastingMetabolic / Body CompositionLow
• Cardiac protection / dysfunctionCardiovascularModerate
• Treatment of GH deficiencyEndocrine / TherapeuticModerate
• IGF-1 elevationMetabolic / HormonalModerate
• Growth hormone stimulationEndocrine / HormonalHigh

Contraindications

• Active malignancyOncologyHighUse caution or avoid depending on agent and context
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Diabetic retinopathyOphthalmologyModerate
• Acromegaly or gigantismEndocrineHigh

Adverse Effects

• HypoglycemiaMetabolicRareAbnormally low blood glucose
• HyperglycemiaMetabolicUncommonAbnormally high blood glucose
• Injection site reactionsLocalCommon
• Carpal tunnel syndromeMusculoskeletalUncommon
• HeadacheNeurologicCommonPain in the head or upper neck
• Tachyphylaxis / GH desensitizationPharmacodynamicCommon
• Water retention / edemaFluid BalanceUncommon
• FlushingVascularCommonWarmth and redness of the skin
• Cortisol and prolactin elevationEndocrineCommon

Drug Interactions

• GlucocorticoidsModerate
• Somatostatin analogs (e.g., octreotide)High
• Insulin / antidiabetic agentsModerate
• CorticosteroidsModerate
• Somatostatin analogues (e.g., octreotide)Moderate

Population Constraints

• Pediatric patientsAgeRelative
• Athletes subject to WADA regulationsRegulatory / SportsAbsolute
• Patients with diabetes mellitusMetabolicRelative
• Elderly patientsAgeRelative
• Children with GH deficiencyPediatricRelative

Regulatory Status

• European UnionInvestigationalUnder clinical evaluation; not authorized.
• United StatesInvestigationalInvestigational New Drug (IND) status; no FDA approval.
• United KingdomInvestigationalNot licensed; available only in research settings.

Not approved for clinical use in any major jurisdiction; studied in Phase I/II trials.

Evidence & Sources

• SARS-CoV-2 RNA Dependent RNA polymerase (RdRp) - A drug repurposing study
  Journal ArticleLowAhmad J, et al.2020-01-01T00:00:00.000000Z
• Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometry
  Journal ArticleLowPobee E, et al.2025-01-01T00:00:00.000000Z
• Gateways to clinical trials
  Journal ArticleLowBayés M, Rabasseda X, Prous JR2002-01-01T00:00:00.000000Z

Frequently Asked Questions